These mutations prevent Aldafermin to activate signal transducer and activator of transcription 3 (STAT3), a signaling pathway essential for FGF19-mediated HCC, while Aldafermin retains its ability to inhibit CYP7A1 (107, 110, 151, 207). This evidence concerns the gene STAT3 and hepatocellular carcinoma.